Thyroid imaging reporting and data system combined with Bethesda classification in qualitative thyroid nodule diagnosis

Huiwen Tan, Zhihui Li, Nong Li, Jianrong Qian, Fengchun Fan, Huiling Zhong, Jinquan Feng, Huajun Xu, Zhongxing Li, Huiwen Tan, Zhihui Li, Nong Li, Jianrong Qian, Fengchun Fan, Huiling Zhong, Jinquan Feng, Huajun Xu, Zhongxing Li

Abstract

Objective: We aimed to investigate the value of the combined use of high-resolution ultrasound thyroid imaging reporting and data system (TI-RADS) classification and thyroid fine needle aspiration cytology (Bethesda classification) for the qualitative diagnosis of benign and malignant thyroid nodules.

Methods: We enrolled 295 patients with 327 thyroid nodules who were scheduled to undergo thyroid nodule surgery. Before surgery, all the patients underwent ultrasound and scoring with the TI-RADS classification, along with thyroid fine needle biopsy cytology under ultrasound guidance (US-FNAC) and scoring with the Bethesda classification. After surgery, the TI-RADS and Bethesda classification scores, separately and in combination, were compared with the postoperative pathological results in terms of the differential diagnosis of thyroid nodules.

Results: TI-RADS classification score 4 exhibited the highest diagnostic value for thyroid cancer; the sensitivity, specificity, and accuracy were 92.7%, 70.7%, and 87.1%, respectively, whereas the Kappa and receiver-operating characteristics (ROC) values were 0.651 and 0.817, respectively. Moreover, Bethesda classification score 3 exhibited the highest diagnostic value for thyroid cancer; the sensitivity, specificity, and accuracy were 90.0%, 94.3%, and 91.1%, respectively, whereas the Kappa and ROC values were 0.78 and 0.914, respectively. With regard to the combined diagnostic method, a score of 7 exhibited the highest diagnostic value for thyroid cancer; the sensitivity, specificity, and accuracy were 97.3%, 92.0%, and 95.9%, respectively, whereas the Kappa and ROC values were 0.893 and 0.946, respectively.

Conclusion: The combination of high-resolution ultrasonography TI-RADS classification and US-FNAC (Bethesda classification) can improve the accuracy of malignant thyroid nodules diagnosis.

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1
Thyroid ultrasound images (thyroid imaging reporting and data system, A–F).
Figure 2
Figure 2
Receiver-operating curves of ultrasound in the evaluation of Bethesda class thyroid nodules. ROC = receiver-operating characteristic.

References

    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–33.
    1. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553–9.
    1. Gharib H, Papini E, Paschke R, et al. AACE/AME/ETA Task Force on Thyroid Nodules. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules. Endocr Pract 2010;16:1–43.
    1. Shan Z, Chen L, Lian X, et al. Iodine status and prevalence of thyroid disorders after introduction of mandatory universal salt iodization for 16 years in China: a cross-sectional study in 10 cities. Thyroid 2016;26:1125–30.
    1. Wang N, Zhou Y, Fu C, et al. The association of thyroid nodule with Non-iodized salt among Chinese children. PLoS One 2014;9:e102726.
    1. Guth S, Theune U, Aberle J, et al. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest 2009;39:699–706.
    1. Kwong N, Medici M, Angell TE, et al. The influence of patient age on thyroid nodule formation, multinodularity, and thyroid cancer risk. J Clin Endocrinol Metab 2015;100:4434–40.
    1. Pacini F, Vorontsova T, Demidchik EP, et al. Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab 1997;82:3563–9.
    1. Lai S, Page JB, Lai H. Solid cancers after bone marrow transplantation. N Engl J Med 1997;336:897–904.
    1. Hegedfis L. Clinical practice. The thyroid nodule. N Engl J Med 2004;351:1764–71.
    1. McLeod DS, Watters KF, Carpenter AD, et al. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose. response meta analysis. J Clin Endocrinol Metab 2012;97:2682–92.
    1. Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology 2011;260:892–9.
    1. Baskin HJ. Ultrasound of Thyroid Nodules. 2000;Boston, MA:Kluwer Academic Publishers, 12(4):71–86.
    1. Shweel M, nansour E. Diagnostic performance of combined elastosonographyscoring and high-resolution uhrasonography for the differentiation of benign and malignant thyroid nodules. Eur J Radiol 2013;82:995–1001.
    1. Rago T, Santini F, Scutari M, et al. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab 2007;92:2917–22.
    1. Cibas ES, Ali SZ. The Bethesda System for reporting thyroid cytopathology. Thyroid 2009;19:1159–65.
    1. Ali SZ, Cibas ES. The Bethesda System for reporting thyroid cytopathology II. Acta Cytol 2016;60:397–8.
    1. Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid 2017;27:1341–6.
    1. Kundel HL, Polansky M. Measurement of observer agreement. Radiology 2003;228:303–8.
    1. Landis JR, Koch GG. The measurement of observer agreement for cate-gorical data. Biometrics 1977;33:157–74.
    1. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reportin system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinal Metab 2009;94:1748–51.
    1. Cheng SP, Lee JJ, Lin JL, et al. Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TI-RADS). Head Neck 2013;35:541–7.
    1. Park JY, Lee HJ, Jang HW, et al. A proposal for a thyroid imaging reporting and data system for ultrasound features of thyroid carcinoma. Thyroid 2009;19:1257–64.
    1. Tessler FN, Middleton WD, Grant EG, et al. ACR Thyroid Imaging, Reporting and Data System(TI-RADS): white paper of the ACR TI-RADS Committee. J AmColl Radiol 2017;14:587–95.
    1. Liu Z, Huang T. Papillary thyroid microcarcinoma: an over-treated malignancy? World J Surg 2016;40:764–5.
    1. Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA 2015;313:926–35. 28.
    1. Kwak JY, Koo H, Youk JH, et al. Value of US correlation of a thyroid nodule with initially benign cytologic results. Radiology 2010;254:292–300.
    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid Nodules and differentiated thyroid cancer:the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1–33.
    1. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules[J]. J Clin Endocrinol Metab 2009;94:2092–8.
    1. Nishino M. Molecular cytopathology forthyroid nodules: a review of methodology and test performance. Cancer Cytopathol 2016;124:14–27.
    1. Perros P, Boelaert K, Colley S, et al. British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf) 2014;81: suppl 1: 1–22.
    1. Durante C, Grani G, Lamartina L, et al. The diagnosis and management of thyroid nodules: a review. JAMA 2018;319:914–24.
    1. Gao LY, Wang Y, Jiang YX, et al. Ultrasound is helpful to differentiate Bethesda class III thyroid nodules: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6564.
    1. Grani G, Lamartina L, Ascoli V, et al. ltrasonography scoring systems can rule out malignancy in cytologically indeterminatethyroid nodules. Endocrine 2017;57:256–61.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅